Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | HTT | P42858 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.71 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.70 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | MMP13 | P45452 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | FAAH | O00519 | 1/20 | 0.62 |
| ▸ | APEX1 | P27695 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19002581 | 0.88 | EPHX2 (0.80) | ALDH1A1HTTSMN1; SMN2EPHX2HPGD | |
| SCHEMBL21254127 | 0.86 | ALDH1A1 (0.74) | ALDH1A1HTTSMN1; SMN2EPHX2HPGD | |
| SCHEMBL5350507 | 0.86 | ALDH1A1 (0.74) | ALDH1A1HTTSMN1; SMN2EPHX2HPGD | |
| SCHEMBL934606 | 0.85 | EPHX2 (0.90) | ALDH1A1HTTSMN1; SMN2EPHX2POLB | |
| SCHEMBL3815151 | 0.85 | ALDH1A1 (0.72) | ALDH1A1HTTSMN1; SMN2EPHX2HPGD | |
| SCHEMBL12964151 | 0.85 | MTNR1A (0.84) | MTNR1AMTNR1B | |
| SCHEMBL933482 | 0.85 | ALDH1A1 (0.56) | ALDH1A1HTTSMN1; SMN2EPHX2MTNR1A | |
| SCHEMBL31512542 | 0.85 | ALDH1A1 (0.72) | ALDH1A1HTTSMN1; SMN2EPHX2HPGD | |
| SCHEMBL8146896 | 0.84 | MTNR1B (0.67) | ALDH1A1HTTSMN1; SMN2EPHX2MTNR1A | |
| SCHEMBL26616786 | 0.84 | ALDH1A1 (0.67) | ALDH1A1HTTSMN1; SMN2EPHX2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3394056-B1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| WO-2017112777-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| US-9586956-B2 | Isoquinoline and naphthyridine derivatives | GENENTECH, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20130029967-A1 | Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2013-01-31 | — | — | US | disclosed |
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2011006935-A2 | TETRAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029967-A1 | Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors | MTOR, PIK3CA, CDK2 | ALDH1A1 2666/4885HTT 3946/4885SMN1; SMN2 2921/4885 |
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | HDAC6, HDAC5, HDAC1 | ALDH1A1 1220/4885HTT 36/4885SMN1; SMN2 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.